



MTPConnect

MedTech and Pharma Growth Centre

TTRA TARGETED TRANSLATION
RESEARCH ACCELERATOR
DIABETES + CARDIOVASCULAR DISEASE

TTRA INFORMATION SESSION: Funding call to establish new Research Centres



WEDNESDAY 20 JANUARY 2021 | 3:30-4:30PM AEDT



Australian Government
Department of Industry, Science,
Energy and Resources

Industry
Growth
Centres

MTPConnect

→ Championing a sector-led approach to accelerating the growth of the
medical technology, biotechnology and pharmaceutical ecosystem in Australia

LET'S GET SOCIAL!



Follow us on
Twitter



Join us on
LinkedIn



Subscribe to the
MTPConnect
Podcast



Follow our MD &
CEO on Twitter



Subscribe to our
email newsletter

CONNECT WITH THE TTRA TEAM



Lauren Kelly

Senior Director | TTRA Program



Dr Mana Liao

Director | TTRA Program



For information please contact
TTRA-DCVD@MTPCONNECT.ORG.AU



MTPConnect
MedTech and Pharma Growth Centre

TTRA TARGETED TRANSLATION
RESEARCH ACCELERATOR
DIABETES + CARDIOVASCULAR DISEASE

TTRA INFORMATION SESSION: Funding call to establish new Research Centres



WEDNESDAY 20 JANUARY 2021 | 3:30-4:30PM AEDT



Australian Government
Department of Industry, Science,
Energy and Resources

Industry
Growth
Centres

MTPConnect

→ Championing a sector-led approach to accelerating the growth of the
medical technology, biotechnology and pharmaceutical ecosystem in Australia

WELCOME & ACKNOWLEDGEMENT OF COUNTRY




Lauren Kelly
Senior Director | TTRA Program

INTRODUCTION









Dr Dan Grant
Managing Director & CEO

ACCELERATING THE GROWTH OF THE MTP SECTOR



OVERVIEW OF MTPCONNECT INITIATIVES

 <p>Australian Government Department of Industry, Science, Energy and Resources</p>  <p>Industry Growth Centres</p>	 <p>BMTH BioMedTech Horizons PROGRAM <small>SUPPORTING TRANSLATION OF AUSTRALIAN MEDICAL TECHNOLOGY INNOVATION</small></p>	 <p>bTb BioMedicaL TRANSLATION BRIDGE PROGRAM</p>	 <p>REDI DEVELOPING AUSTRALIA'S MTP SECTOR WORKFORCE <small>Researcher Exchange & Development within Industry Initiative Program</small></p>	 <p>TTRA TARGETED TRANSLATION RESEARCH ACCELERATOR <small>DIABETES · CARDIOVASCULAR DISEASE</small></p>
Department of Industry, Science, Energy and Resources	Department of Health Medical Research Future Fund	Department of Health Medical Research Future Fund	Department of Health Medical Research Future Fund	Department of Health Medical Research Future Fund
\$15.6M	\$45M	\$22.3M	\$32M	\$47M
<ul style="list-style-type: none">▪ Fully committed▪ 36 Projects	<ul style="list-style-type: none">▪ Largely committed▪ 39 projects	<ul style="list-style-type: none">▪ Fully committed▪ 21 projects▪ 3 program partners	<ul style="list-style-type: none">▪ 9 program partners▪ Building the MTP workforce▪ Addressing skills gaps▪ Enhancing entrepreneurial ecosystem	<ul style="list-style-type: none">▪ D&CVD focus▪ 3 program partners▪ Establish two Research Centres▪ Annual funding rounds for Research Projects

GOVERNANCE



Prof. Ian Frazer AC (Chair)

Professor of Medicine
University of Queensland



Hon. Judi Moylan AO

Former Chair
Diabetes Australia



Adj/Prof John Kelly AM

Chief Executive Officer
Heart Foundation



Mike Wilson OAM

Chief Executive Officer
JDRF



Rebecca Davies AO

Director, Lifehouse
Director, The Actuator



Prof. James Best AO

Dean
Lee Kong Chian School of Medicine



Prof. Rachel Huxley

Executive Dean – Faculty of Health
Deakin University



Yasser El-Ansary

Chief Executive Officer
Australian Investment Council

MRFF \$47 MILLION - TTRA PROGRAM



RESEARCH CENTRES (Pillar 1)

CENTRE #1

CENTRE #2

Needs Assessment

DIABETES
COMPLICATIONS



CARDIOVASCULAR
DISEASE
COMPLICATIONS



RESEARCH PROJECTS (Pillar 2)

Round 1

Round 2

Round 3

Needs
Assessment

D&CVD



Needs
Assessment

D&CVD



Needs
Assessment

D&CVD



PARTNERS



UNIQUEST

Year 0

Year 1

Year 2

Year 3

Year 4

NEEDS ASSESSMENT

Needs Assessment Partners:



MONASH
SUSTAINABLE
DEVELOPMENT
INSTITUTE

BehaviourWorks
AUSTRALIA

RESEARCH
AUSTRALIA
CONNECTING • ENGAGING • INFLUENCING

SCOPE

318 individuals

LONG LIST

>900 priorities

SHORT LIST

19-29 unique areas

COMMUNICATE

Early 2021

PRIORITY AREAS

RESEARCH CENTRE - DIABETES



1	Diabetic kidney disease
2	Peripheral neuropathy and diabetic foot syndrome
3	Short-term complications of hypoglycaemia and/or hyperglycaemic hyperosmolar syndrome (HHS) and ketoacidosis

RESEARCH CENTRE - CVD




1	Coronary artery disease (including angina and MACE)
2	Cardiomyopathy / heart failure
3	Transient ischaemic attack (TIA) / stroke (ischaemic and haemorrhagic)

INTRODUCTION



Prof Ian Frazer AC FRS
Chair, TTRA Expert Advisory Board

RESEARCH CENTRES OVERVIEW



\$20M

\$10M for each
Research Centre
over four years



Diabetes
Research Centre



National
partnership



Clinical adoption &
implementation



CVD
Research Centre



Innovative & diverse
modalities



Health economic
outcomes

RESEARCH CENTRE



RESEARCH PORTFOLIO

Translational R&D,
implementation science



TRAINING PROGRAM

Supervision of postgrad students,
industry internship, mentoring,
training



SUSTAINABILITY PLAN

Strategy to continue financial
viability and talent management

PARTNERING SUMMIT



INTRODUCTION




Dr Mana Liao

Director | TTRA Program

ELIGIBILITY

- **Lead Applicant**
- **Minimum two** independent partner organisations.
- Partner organisations **can include** but are not limited to: MRIs, universities, NFP organisations, commercial entities (SMEs/Industry), consumer / advocacy groups
- Research Centre partners receiving TTRA funding **must have an Australian Business Number (ABN)**
- **International entities** are eligible to be a Research Centre **partner**, but cannot receive TTRA funding
- Research Centre partners **must control or have legal right to access and use relevant IP**
- Investigators **can submit multiple applications** and **apply for both Research Centre and Research Projects**. But the same investigator cannot be the lead for both Research Centres.

APPLICATION PROCESS



SELECTION CRITERIA

	Selection Criterion	Weighting
1	Research & Clinical Impact <ul style="list-style-type: none">▪ Research Portfolio	30%
2	Sustainability <ul style="list-style-type: none">▪ Sustainability Plan▪ Training Program	30%
3	Capacity, Capability & Resources <ul style="list-style-type: none">▪ Partnership	30%
4	Overall Value & Risk <ul style="list-style-type: none">▪ Budget	10%

Research Centres

Expressions Of Interest Now Open

This opportunity is offered by the Commonwealth under the Targeted Translation Research Accelerator (TTRA) Program which forms part of the Medical Research Future Fund (MRFF) to support the establishment of two Research Centres.

The TTRA Research Centres will accelerate therapies towards clinical practice for the prevention, diagnosis, treatment and management of disease-related complications for identified priorities associated with diabetes or cardiovascular disease, respectively.

Each Research Centre will be funded to a maximum of \$10 million over four years. Partnerships and co-contributions are strongly encouraged and investigation in diverse clinical and therapeutic treatment modalities will be viewed favourably.

Each Research Centre must focus on at least two of the identified Priority Areas, with favourable recognition given to proposals addressing all three Priority Areas.

The Diabetes Research Centre's translational research, development and implementation science activities must address at least two of the following Priority Areas:

- Priority 1: Diabetic kidney disease;
- Priority 2: Peripheral neuropathy and diabetic foot syndrome;
- Priority 3: Short-term complications of hypoglycaemia and/or hyperglycaemic hyperosmolar syndrome (HHS) and ketoacidosis.

The Cardiovascular Disease Research Centre's translational research, development and implementation science activities must address at least two of the following Priority Areas:

- Priority 1: Coronary artery disease (including angina and MACE);
- Priority 2: Cardiomyopathy / heart failure;
- Priority 3: Transient ischaemic attack (TIA) / stroke (ischaemic and haemorrhagic).

The Research Centres must also demonstrate how adoption and implementation of their therapies will subsequently deliver health system outcomes, public health policy outcomes, consumer outcomes, commercial outcomes and reduce the burden of disease and health inequalities in Australia. It is expected that each Research Centre will have a strategy to become sustainable to ensure continued financial viability and talent management of the entity beyond the four years of TTRA funding. In addition to research and development, each Research Centre must include a training undertaking as part of its activities.

Please review the detailed Guidelines for further information about eligibility and the application process. All submissions must be made through SmartyGrants with a link provided below. The sample EOI application form provides an overview of what is required in your EOI.

Submissions will close at 16:00 AEDT on 15 March 2021.

Join the TTRA Research Centres Information Session via webinar on 20 January 2021 at 15:30 AEDT. Register [here](#).

For queries, please contact the TTRA team via email on ttra-dcvd@mtpconnect.org.au.

GUIDELINES

SAMPLE EOI APPLICATION FORM

APPLY NOW

TTRA RESEARCH CENTRES

- EOI now open!
- Submissions will close at **16:00 AEDT on 15 March 2021**

www.mtpconnect.org.au

Questions?



- Please enter them in the Q&A box
- You can tick the ANONYMOUS checkbox
- UPVOTE existing questions

Thanks for connecting with us.

- Please take a moment to leave us some FEEDBACK
- Just CLICK THE SURVEY LINK that will appear when you log out. Yes, it is ANONYMOUS and QUICK!



For further information please contact:
TTRA-DCVD@MTPCONNECT.ORG.AU